Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

BioNTech SE is currently sponsoring a Phase II clinical study titled A Phase II, Multisite, Open-label, Single Arm Trial of BNT327 in Combination With Docetaxel in Second-line Stage IV Non-small Cell ...

The chapter on Pfizer and BioNTech’s mRNA patent feud with Germany’s CureVac is coming to a close, even as lawsuits over the ...

Pfizer Canada ULC and BioNTech SE (Nasdaq: BNTX) "BioNTech" announced today that Health Canada has authorized the LP.8.1 ...

Germany's CureVac and Britain's GSK have settled a years-long patent dispute with Pfizer and its partner BioNTech over the ...

Pfizer's Canadian unit and BioNTech said they have received approval in Canada for their updated Comirnaty Covid-19 vaccine. The companies said Monday the updated vaccine targets the Omicron LP.8.1 ...

The deal helps move BioNTech’s proposed acquisition of CureVac closer to completion. With the settlement, GSK said it will tender the CureVac shares it owns in support of the $1.25 billion acquisition ...

BioNTech (BNTX) recently experienced a 10% price increase in the last quarter, coinciding with the Health Canada's authorization of its variant-adapted COMIRNATY COVID-19 vaccine, a potential positive ...

The complex settlement, which hands payouts and royalties to CureVac and partner GSK, comes as BioNTech is inching toward an ...

GSK and CureVac will together receive $740 million, as well as royalties on sales of COVID-19 vaccines in the US ...

The top executives running the health care industry’s blue-chip companies amassed generational wealth in 2024, even as many ...

Moderna is not asking that courts take the Pfizer-BioNTech COVID-19 vaccine off the market or to stop future sales, in view of the public need for the vaccines. Moderna and Pfizer's vaccines have ...